Inhibition of PD-L1 glycosylation in tumor cells can enhance T cell-mediated anti-tumor immune response in breast cancer, suggesting that glycosylation is related to PD-L1 mediated tumorigenic effect (122). The gene discussed is CD274; the disease is breast carcinoma.